Breadcrumb Home Resources and Information Physicians and Scientists Resource Hub Exploring The Potential of Vamotinib In Ph+ Leukemias: Is It Indeed a 3rd Generation Tyrosine Kinase Inhibitor? Exploring the potential of vamotinib in Ph+ leukemias: Is it indeed a 3rd generation tyrosine kinase inhibitor? Journal of Hematology & Oncology , Nov 2026 Lucini C et al. J Hematol Oncol, October 2026 Link to full abstract Share Tweet Share Share